Led · Equity · May 2026

MiRus is developing the investigational SIEGEL balloon-expandable TAVR system, designed with a proprietary nitric oxide–coated rhenium alloy to provide a nickel-free valve construct. The SIEGEL valve features an open-cell frame intended to eliminate foreshortening for more precise placement, dry porcine tissue leaflets, and can be delivered through an 8 French expandable sheath across 23 mm, 26 mm, and 29 mm sizes. The device remains investigational and has not been approved for commercial distribution; MiRus has presented early feasibility data and recently launched the STAR pivotal trial enrolling up to 1,025 patients at varying surgical risk levels. The company is working with an Atlanta-based team and reported enthusiastic investigator feedback on delivery and hemodynamics. Financially, MiRus secured a $1.5 billion strategic investment from Boston Scientific that conveys a ~34% stake and includes options and milestone-linked payments that could total several billion dollars tied to clinical, regulatory, and sales milestones.

Participated · Series D · Aug 2025

SetPoint Medical is a commercial-stage medical technology company headquartered in Valencia, Calif., focused on therapies for chronic autoimmune diseases. Its FDA‑approved SetPoint System is the first neuroimmune modulation therapy for adults with moderate-to-severe rheumatoid arthritis, providing a device-based alternative for patients who do not respond to or cannot tolerate biologic or targeted drug therapies. The company’s proprietary integrated neurostimulation platform is designed to activate innate anti-inflammatory pathways in the vagus nerve to reduce inflammation and restore immunologic setpoint. Proceeds from the recent financing will support commercialization of the SetPoint System in select U.S. markets this year and broader national expansion in 2026, and will also fund advancement of the company’s pipeline in other autoimmune conditions. SetPoint plans to evaluate its platform for additional indications including multiple sclerosis and Crohn’s disease. In conjunction with the fundraise the company expanded its leadership team and board to support commercialization and market access efforts. SetPoint Medical is a privately held clinical-stage healthcare company focused on treating chronic autoimmune diseases. The company is developing a novel platform that stimulates the vagus nerve to activate the inflammatory reflex and produce a systemic immune-restorative effect. The SetPoint system is a miniaturized stimulation device placed on the vagus nerve through a small incision on the left side of the neck in an outpatient procedure and delivers stimulation on a preset schedule. The platform is being developed as an alternative for patients with rheumatoid arthritis who have an incomplete response to or are intolerant of biologic drugs, and is also intended for inflammatory bowel disease and other chronic autoimmune conditions. SetPoint is advancing the RESET-RA study and preparing U.S. FDA regulatory submissions and early commercialization for the RA indication. Financially, the company recently announced an $80 million equity financing and expanded a senior secured term loan facility of up to $65 million with Runway Growth Capital to support development and early commercial activities. SetPoint Medical develops a bioelectronic medicine platform designed to stimulate the vagus nerve and activate the body’s inflammatory reflex to produce a systemic immune‑restorative effect for chronic autoimmune diseases. The company is pursuing electrical‑pulse therapies as a potentially safer, lower‑cost alternative to drugs and biologics for conditions including rheumatoid arthritis and inflammatory bowel disease. SetPoint is clinical‑stage and is advancing its technology through the RESET‑RA study, which will evaluate safety and efficacy in patients with moderate‑to‑severe RA. The $35 million financing announced will support the ongoing RESET‑RA trial and other development activities. SetPoint is privately held, was founded in 2007, and is based in Valencia, California. The articles do not disclose revenue or user metrics. SetPoint Medical is a privately held, clinical‑stage bioelectronic medicine company developing a platform that stimulates the vagus nerve to activate the inflammatory reflex and reduce systemic inflammation. The company is initially focused on a less immunosuppressive therapeutic option for patients with rheumatoid arthritis (RA) and is also developing applications for inflammatory bowel disease and other chronic autoimmune conditions. SetPoint’s investigational device is intended to offer an alternative to biologic and targeted drug therapies with potentially lower risk and cost. The company has received Breakthrough Device designation from the U.S. FDA for use in RA patients who are incomplete responders to, or intolerant of, multiple biologic drugs. Proceeds from the financing will support the RESET‑RA multicenter, double‑blind, randomized, sham‑controlled pivotal trial that will enroll up to 250 patients at 40 U.S. sites to evaluate safety and effectiveness. SetPoint converts neurostimulation of the vagus nerve into a systemic immune‑restorative effect and is positioning its platform toward regulatory‑pathway clinical validation. SetPoint Medical is developing a proprietary bioelectronic medicine platform that uses a small implanted device to activate the body’s Inflammatory Reflex and produce a systemic anti-inflammatory effect. The company’s core product is an implanted stimulator that targets the vagus nerve as an alternative to drug therapies for chronic inflammatory diseases. SetPoint has published positive results from a first‑in‑human proof‑of‑concept trial in rheumatoid arthritis in PNAS and presented positive data at the American College of Rheumatology meeting. The company positions its approach as potentially lower risk and lower cost compared with current biologic treatments. SetPoint plans to use the new financing to advance clinical development and enable its next clinical trial in rheumatoid arthritis. It is a privately held company focused on commercializing bioelectronic medicines for debilitating inflammatory diseases.

Participated · Series D · Apr 2024

Nectero Medical is developing the Nectero EAST System, an investigational single-use endovascular system that delivers pentagalloyl glucose (PGG) locally into the aneurysmal wall to bind elastin and collagen and potentially strengthen the aortic vessel wall. The procedure is performed in under an hour, leaves no permanent implant, and does not preclude future interventions; early clinical results from a first-in-human study were published in the Journal of Vascular Surgery. The company initiated a Phase II/III stAAAble trial in January 2024 to evaluate safety and efficacy in infrarenal AAAs (3.5–5.0 cm), and the Nectero EAST System received Fast Track and Breakthrough Therapy designations. Nectero positions the therapy as a potential first approved option for smaller AAAs beyond surveillance if trials are successful. The company cites a large addressable population (over 1M diagnosed Americans and ~60,000 treated annually) and will use recent financing to advance clinical work and regulatory submission. Its lead product aims to offer a minimally invasive alternative to current surveillance or treatments reserved for larger or symptomatic AAAs. Nectero Medical is developing the Endovascular Aortic Stabilization Treatment (EAST), a one-time catheter-based procedure that locally delivers a proprietary compound to stabilize small- to mid-sized aortic aneurysms and leave no implant behind. The EAST system has shown early clinical results and is currently treating AAA patients in a multi-site Phase 1 safety study. The therapy is intended to significantly reduce aneurysm growth rate, prevent rupture, and provide an option for patients who are managed with active surveillance or are ineligible for surgical repair. Proceeds from the recent financing will support in vivo and clinical trials to advance the platform. The company also cites potential broader applications including thoracic aneurysms, aortic dissections, neurovascular aneurysms, and other cardiovascular and connective tissue disorders. The company is based in Tempe, Ariz.

Participated · Series B · Jul 2020

Preventice Solutions delivers digital healthcare solutions and remote cardiac monitoring services using deep learning and AI. Its product portfolio includes the cloud-based PatientCare subscription platform, the BodyGuardian® MINI family of monitors (covering short- and long-term Holter, cardiac event monitoring and mobile cardiac telemetry) and the BeatLogic® analytics engine. Preventice reports over a decade of experience, having monitored millions of patients and supporting thousands of practices nationwide. In May 2020 the company published Heart Rhythm Journal data showing BeatLogic outperformed leading algorithms on AFib and VEB classification in MIT datasets. The company plans to use new capital to accelerate salesforce expansion, invest in technology and product innovation, and further develop clinical evidence for its flagship solutions. Preventice emphasizes integration with physicians, payers and Integrated Delivery Networks through PatientCare and electronic medical record integration capabilities. Preventice Solutions develops mobile health monitoring technologies and services that connect patients and caregivers. Its product portfolio includes the PatientCare Platform and the BodyGuardian® range — BodyGuardian® Heart, BodyGuardian® Verité and BodyGuardian® Holter. The company is led by co-CEOs Jon Otterstatter (President and Chief Global Strategy Officer) and John Untereker (Executive Vice President and Chief Operating Officer). Preventice received an equity investment from Boston Scientific. As part of the arrangement, Boston Scientific will become the exclusive worldwide sales and marketing representative for cardiology-related diagnostic and monitoring offerings, indicating a strategic commercial partnership and go-to-market plan. The company is based in Minneapolis, MN.

Participated · Equity · Jun 2019

Saluda Medical develops a proprietary closed-loop, dose-control neuromodulation platform and is commercial-stage with its first product, the Evoke® System. The Evoke System is a physiologic closed-loop spinal cord stimulation (SCS) system that senses neural responses and automatically adjusts therapy to maintain a targeted level of neural activation. The system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including failed back surgery syndrome, intractable low back pain, leg pain, and chronic neuropathic pain. Saluda cites randomized, multi-center pivotal-study results with 12-month data published in The Lancet Neurology, 24-month results in JAMA Neurology, and 36-month data in Regional Anesthesia and Pain Medicine. Net proceeds from the financing will be used primarily to advance commercialization of the Evoke System. The company is continuing commercial efforts from its Minneapolis base. Saluda Medical, based in Artarmon, Australia, advances a portfolio of therapies driven by advanced closed‑loop technologies for debilitating neurological disorders. Its first product is the Evoke SmartSCS System, an ECAP‑controlled closed‑loop spinal cord stimulation (SCS) system. The Evoke System is indicated as an aid in the management of chronic intractable trunk and/or limb pain, including pain associated with failed back surgery syndrome and intractable low back and leg pain. The device automatically reads, records, and responds to nerves’ responses to stimulation more than 4 million times a day to continually optimize therapy. The company states the Evoke System is proven to be superior to open‑loop SCS for treatment of overall trunk and/or limb pain. Saluda is led by President and CEO Jim Schuermann and is advancing its technology platform alongside commercial plans for Evoke. Saluda Medical is a medical device company developing the Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) System to treat chronic intractable pain of the trunk and limbs. The Evoke system measures the spinal cord’s response to stimulation via evoked compound action potentials (ECAPs) and adjusts on every pulse to maintain activation within a patient’s therapeutic window. Saluda is advancing Evoke through the first double-blinded, randomized, controlled U.S. pivotal study and is pursuing regulatory approval to market the system. The company intends to use newly raised capital to fund final development stages through commercialization. Saluda is led by CEO John Parker and has offices in Artarmon, Australia; Bloomington, Minnesota; and Harrogate, UK. Saluda Medical Pty Limited is a medical device company developing a platform of closed-loop neuromodulation technologies based on neural response to stimulation. The platform is built to sense neural responses and adapt stimulation accordingly. The company is based in Australia. Saluda secured A$53 million (US$40 million) in an all-equity financing round. That financing was reported as a Series D led by Action Potential VC. Saluda Medical is a Sidney, Australia-based provider of technology and devices to treat chronic pain and other conditions. The company develops Evoke™, a spinal cord stimulation system designed to treat chronic pain of the trunk and limbs. Its neuromodulation technology measures nerve signals and adjusts stimulation in real time. Saluda is exploring applications of its platform for Parkinson's disease, epilepsy and other debilitating disorders. The company plans to use recently raised funds to conduct chronic clinical trials and support commercialization of Evoke. Saluda is a spin-out from NICTA and is led by CEO John Parker.